Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net income (loss)	$ 13,542	$ (28,502)
Adjustments to reconcile net income (loss) to net cash provided by, (used in) operating activities:
Provision for (recovery of) bad debts	660	(574)
Deferred tax expense	(30,928)	(7,036)
Depreciation and amortization	71,207	19,454
Amortization of debt discount and issuance costs	5,003	13,653
Equity-based compensation	11,677	11,706
Contingent consideration	(5,981)	1,071
Warranty provision	4,341	305
Provision for inventory obsolescence	(2,333)	654
Changes in operating assets and liabilities, net of business acquisition
Accounts receivable	(139,036)	(50,840)
Inventories	(14,273)	(55,321)
Income tax receivables	(3,610)	9,676
Prepaid expenses and other	11,146	(5,770)
Accounts payable	42,205	1,948
Accounts payable - related party	(132)	(1,622)
Accrued expenses and other	41,271	1,683
Warranty payments	(373)	0
Income tax payable	2,951	(8,185)
Lease liabilities	1,914	337
Deferred revenue	34,772	(68,474)
Net cash provided by, (used in) operating activities	44,023	(165,837)
Cash flows from investing activities
Purchase of property, plant and equipment	(6,690)	(2,252)
Acquisition of STI, net of cash acquired	(373,816)	0
Investment in equity security	0	(11,975)
Net cash used in investing activities	(380,506)	(14,227)
Cash flows from financing activities
Proceeds from Series A issuance	33,098	224,987
Proceeds from common stock issuance	15,885	120,645
Series A equity issuance costs	(1,167)	(7,195)
Common stock issuance costs	(450)	(3,873)
Dividends paid on Series A Preferred	(18,670)	0
Payments on revolving credit facility	(116,000)	(102,000)
Proceeds from issuance of other debt	39,219	0
Proceeds from revolving credit facility	116,000	102,000
Principal payments on debt	(33,286)	(132,150)
Contingent consideration	(1,483)	(7,810)
Debt issuance costs	0	(6,590)
Net cash provided by financing activities	33,146	188,014
Effect of exchange rate changes on cash and cash equivalent balances	(1,555)	0
Net change in cash and cash equivalents	(304,892)	7,950
Cash and cash equivalents, beginning of period	367,670	108,441
Cash and cash equivalents, end of period	62,778	116,391
Supplemental Cash Flow Information
Stock consideration paid for acquisition of STI	$ 200,224	$ 0